Cable Hill Partners’s Adverum Biotechnologies ADVM Stock Holding History

Cable Hill Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-150	Closed	-$8K	–	884
2018 Q1	$8K	Buy	+150	New	+$9.34K	﹤0.01%	523

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cable Hill Partners's ADVM Position: Q2 2019 in Review

Cable Hill Partners sold out of Adverum Biotechnologies (ADVM) in Q2 2019, closing a stake of 250 shares — an estimated $13K sold.

Cable Hill Partners first reported a position in ADVM in Q4 2017 and held it in 6 quarters. The position peaked at $19K in Q2 2018. 94 funds tracked by Wall St. Rank hold ADVM as of Q2 2019.

Cable Hill Partners reported no remaining Adverum Biotechnologies position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 250 Adverum Biotechnologies shares in Q2 2019, an estimated $13K.
Cable Hill Partners first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 6 quarters.
Cable Hill Partners's Adverum Biotechnologies position peaked at $19K in Q2 2018.
94 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.